Structural basis for EROS binding to human phagocyte NADPH oxidase NOX2.

Humans NADPH Oxidase 2 / metabolism Phagocytes / metabolism NADPH Oxidases / metabolism Cryoelectron Microscopy Protein Binding Binding Sites Granulomatous Disease, Chronic / metabolism Models, Molecular Reactive Oxygen Species / metabolism
EROS NADPH oxidase NOX2 chronic granulomatous disease neutrophils

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
04 Jun 2024
Historique:
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 28 5 2024
Statut: ppublish

Résumé

Essential for reactive oxygen species (EROS) protein is a recently identified molecular chaperone of NOX2 (gp91

Identifiants

DOI: 10.1073/pnas.2320388121 PMID: 38805284
pubmed: 38805284
doi: 10.1073/pnas.2320388121
doi:

Substances chimiques

NADPH Oxidase 2 EC 1.6.3.-
CYBB protein, human EC 1.6.3.-
NADPH Oxidases EC 1.6.3.-
Reactive Oxygen Species 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2320388121

Subventions

Organisme : MOST | National Key Research and Development Program of China (NKPs)
ID : 2019YFA0906003
Organisme : Science, Technology and Innovation Commission of Shenzhen Municipality ()
ID : GXWD20201231105722002- 20200831175432002
Organisme : MOST | National Natural Science Foundation of China (NSFC)
ID : 32070950
Organisme : China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
ID : 2022M713049
Organisme : Shenzhen Municipal Science and Technology Innovation Council | Shenzhen Science and Technology Innovation Program ()
ID : RCBS20221008093330067

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Shiyu Liang (S)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
ORCID: 0009-0002-0261-3727

Aijun Liu (A)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
Dongguan Songshan Lake Central Hospital, Dongguan Third People's Hospital, Dongguan, Guangdong 523326, China.

Yezhou Liu (Y)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
Institute of Infectious Diseases, Shenzhen Bay Laboratory, Guangming District, Shenzhen 518132, China.
ORCID: 0000-0001-7575-8260

Fuxing Wang (F)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
ORCID: 0009-0005-0812-183X

Youli Zhou (Y)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.

Yuanzhengyang Long (Y)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
ORCID: 0009-0009-7909-3230

Tao Wang (T)

Institute of Infectious Diseases, Shenzhen Bay Laboratory, Guangming District, Shenzhen 518132, China.
Key Laboratory of Computational Chemistry and Drug Design, Peking University Shenzhen Graduate School, Nanshan District, Shenzhen 518055, China.

Zheng Liu (Z)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
ORCID: 0000-0002-3538-9349

Ruobing Ren (R)

Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China.
ORCID: 0000-0003-4517-7216

Richard D Ye (RD)

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
The Chinese University of Hong Kong, Shenzhen Futian Biomedical Innovation R&D Center, Shenzhen, Guangdong 518000, China.
ORCID: 0000-0002-2164-5620

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Structural basis for EROS binding to human...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › NADPH oxidase › NADPH Oxidase 2 › Structural basis for EROS binding to human...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Structural basis for EROS binding to human...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › NADPH oxidase › Structural basis for EROS binding to human...
questionsmedicales.fr › Techniques d'investigation › Microscopie électronique › Cryomicroscopie électronique › Structural basis for EROS binding to human...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Structural basis for EROS binding to human...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › Structural basis for EROS binding to human...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Granulomatose septique chronique › Structural basis for EROS binding to human...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › Structural basis for EROS binding to human...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Espèces réactives de l'oxygène › Structural basis for EROS binding to human...